BMJ 1994;309:355-6 (6 August)

Editorials

Ulcerative colitis and Crohn's disease

In the past four years three excellent and comprehensive books on inflammatory bowel disease have been published.*RF 1-3* In a total of 1812 pages 156 contributors provide detailed accounts of the recent striking rise in the incidence of Crohn's disease but not ulcerative colitis in most developed countries; patients' genetic disposition (the dis-eases are apparently not HLA related); and clinical features, immunology, pathology, complications, and management options. Can there be much left to find out? Regrettably for the 120 000 or so patients with inflammatory bowel disease in Britain, from toddlers to octogenarians, the answer is yes. And despite inflam-matory bowel disease being unfashionable and attracting little research funding, there is a wealth of research going on.

Theories of the cause of inflammatory bowel disease abound. Current front runners include a range of types of immune dysregulation, such as abnormally vigorous stimulation of the gut immune system by products of . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Marier, J.-F., Beliveau, M., Mouksassi, M.-S., Shaw, P., Cyran, J., Kesavan, J., Wallens, J., Zahir, H., Wells, D., Caminis, J. (2008). Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon-Like Peptide-2 (GLP-2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects. J Clin Pharmacol 48: 1289-1299 [Abstract] [Full text]  
  • Chen, C.-M., Gong, Y., Zhang, M., Chen, J.-J. (2004). Reciprocal Cross-talk between Nod2 and TAK1 Signaling Pathways. J. Biol. Chem. 279: 25876-25882 [Abstract] [Full text]  
Access jobs at BMJ Careers
Whats new online at Student BMJ